Skip to content
Boca Raton City Online – Lifestyle
Author:
Moderna, Inc.
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
April 15, 2026
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
April 7, 2026
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
March 9, 2026
European Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19
March 8, 2026
Moderna to Present at Upcoming Conferences in March 2026
March 7, 2026
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
March 7, 2026
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
March 6, 2026
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
March 6, 2026
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
March 5, 2026
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
March 5, 2026
←
Previous Page
1
2
3